Implants and endoprostheses are always exposed to the risk of colonisation by germs, bacteria and biofilm formation after insertion into the human body, resulting in infections, usually mixed infections, in 0.5% to 2% of cases. The risk of infection increases with the implant volume and depending on the implantation site. This explains why the infection rate for tumour prostheses or megaprostheses for the reconstruction of a usually pronounced defect section is significantly higher, with an infection risk of up to 20 %. If further complications occur, the risk rises to approx. 40 % for secondary revision procedures. An increasing number of prosthesis infections is predicted for the future.

To solve the above-mentioned problems, we have developed a new type of coating made of body-related substances with definable release kinetics of the active substances contained and selectively activatable properties, which will be subjected to mechanical, physical and microbiological tests in the next step in preparation for approval as a medical device.

We have an interdisciplinary team of doctors, engineers and scientists to successfully complete our project.